This bill mandates that health insurance carriers in New Jersey provide coverage for genetic testing following a diagnosis of pancreatic adenocarcinoma. It applies to various types of health insurance contracts, including those from hospital service corporations, medical service corporations, health service corporations, health maintenance organizations, and entities involved in the State Health Benefits Program or School Employees Health Benefits Program. The coverage for genetic testing must be equivalent to that provided for any other medical condition under the respective insurance contracts.

The bill defines "genetic test" as a medical test that analyzes an individual's DNA, RNA, chromosomes, or proteins to identify genetic changes or mutations related to pancreatic adenocarcinoma and other cancers. This testing is intended to assist in monitoring, treatment decisions, and management for individuals diagnosed with pancreatic adenocarcinoma, and it encompasses various forms of testing, including germline testing and tumor molecular profiling. The act is set to take effect four months after its enactment and will apply to all relevant policies and contracts issued or renewed thereafter.